Financial Advisory Service Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,084 shares of the company’s stock after buying an additional 103 shares during the period. Financial Advisory Service Inc.’s holdings in Eli Lilly and were worth $512,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. First Command Financial Services Inc. raised its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the period. LeJeune Puetz Investment Counsel LLC bought a new stake in Eli Lilly and during the fourth quarter valued at approximately $136,000. Crestwood Advisors Group LLC bought a new stake in Eli Lilly and during the first quarter valued at approximately $179,000. Alpha Windward LLC raised its stake in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares during the period. Finally, ARS Investment Partners LLC bought a new stake in Eli Lilly and during the fourth quarter valued at approximately $202,000. 75.48% of the stock is currently owned by institutional investors and hedge funds.

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.13% during trading on Thursday, reaching $81.93. The company had a trading volume of 3,688,344 shares. The firm’s 50 day moving average price is $82.99 and its 200 day moving average price is $81.53. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The firm has a market capitalization of $90.20 billion, a P/E ratio of 35.31 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.50% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.86 EPS. Equities analysts predict that Eli Lilly and Company will post $4.15 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/03/financial-advisory-service-inc-acquires-103-shares-of-eli-lilly-and-company-lly-updated-updated-updated.html.

LLY has been the topic of several analyst reports. BMO Capital Markets set a $71.00 target price on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Monday, July 17th. Credit Suisse Group reissued an “outperform” rating and issued a $87.00 price objective on shares of Eli Lilly and in a report on Wednesday, April 19th. Barclays PLC raised their price objective on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, April 7th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $92.00 price objective (down from $94.00) on shares of Eli Lilly and in a report on Saturday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $88.37.

In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now directly owns 124,265,804 shares in the company, valued at approximately $10,491,761,831.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.